Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Trial Profile

Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi Pasteur Holding
  • Most Recent Events

    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12605000575639).
    • 26 Jan 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 26 Jan 2009 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top